Welcome to our dedicated page for Ligand Pharma SEC filings (Ticker: LGNZZ), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Ligand Pharms Beta CVR filings document Ligand Pharmaceuticals Incorporated material-event disclosures, license-agreement matters, capital-structure information, operating and financial results, and proxy governance. The filing record includes Form 8-K reports on material definitive agreements and TR-Beta Program disclosures involving VK2809 and VK0214, as well as definitive proxy materials covering board matters, executive compensation, equity awards, and shareholder voting.
Ligand Pharmaceuticals director John W. Kozarich sold 467 shares of common stock in a planned transaction. The sales occurred on February 2, 2026 at prices ranging from $191.00 to $197.195 per share in several small trades.
After these sales, Kozarich directly beneficially owned 43,187 shares of Ligand common stock. The filing notes that the transactions were executed under a written trading plan adopted on March 7, 2025 in accordance with Rule 10b5-1, which allows pre-arranged trading by insiders.
Ligand Pharmaceuticals director John W. Kozarich sold 467 shares of common stock in a planned transaction. The sales occurred on February 2, 2026 at prices ranging from $191.00 to $197.195 per share in several small trades.
After these sales, Kozarich directly beneficially owned 43,187 shares of Ligand common stock. The filing notes that the transactions were executed under a written trading plan adopted on March 7, 2025 in accordance with Rule 10b5-1, which allows pre-arranged trading by insiders.
Ligand Pharmaceuticals insider selling notice: A Form 144 reports a planned sale of 467 shares of Ligand common stock through UBS Financial Services Inc., with an aggregate market value of 89,748.06. The shares are listed on Nasdaq, and 19,681,720 shares were outstanding at the time referenced.
The shares to be sold are common stock acquired on 04/24/2024 from the issuer in various transactions, totaling 467 shares. The filing also notes that John Kozarich has sold 467 common shares in each of three transactions over the past three months, with gross proceeds of 91,456.91, 89,219.00, and 88,532.51.
Ligand Pharmaceuticals insider selling notice: A Form 144 reports a planned sale of 467 shares of Ligand common stock through UBS Financial Services Inc., with an aggregate market value of 89,748.06. The shares are listed on Nasdaq, and 19,681,720 shares were outstanding at the time referenced.
The shares to be sold are common stock acquired on 04/24/2024 from the issuer in various transactions, totaling 467 shares. The filing also notes that John Kozarich has sold 467 common shares in each of three transactions over the past three months, with gross proceeds of 91,456.91, 89,219.00, and 88,532.51.
Form 144 notice for proposed sale of 10,000 common shares by an insider through Morgan Stanley Smith Barney LLC. The filing states the aggregate market value of the shares to be sold is $1,708,087.44 based on 10,000 shares, with approximately 19,596,560 shares outstanding for the issuer. The approximate date of sale is listed as 09/23/2025. The filer reports no securities sold in the past three months. Acquisition details show the 10,000 shares were acquired in multiple lots between 06/04/2022 and 06/06/2025 via restricted stock grants and exercised share transactions, with specific lot sizes and payment methods noted where applicable.
Form 144 notice for Ligand Pharmaceuticals, Inc. (LGNZZ): An insider filed to sell 10,000 shares of the company's common stock through Charles Schwab & Co., with an approximate aggregate market value of $1,685,000. The filing reports the shares were acquired in the open market on October 9, 2014 (payment dated October 1, 2014) and the proposed sale date is September 17, 2025 on NASDAQ. The filing states there were 19,596,560 shares outstanding, and no securities were sold by the filer in the past three months. The filer certifies no undisclosed material information is known.
Ligand Pharmaceuticals Incorporated reported that it entered into a Third Amendment to its existing credit agreement with Citibank and other lenders. The amendment extends the loan’s maturity date to September 12, 2028, giving the company more time before the debt comes due.
The amendment also tightens a key financial test. Ligand must maintain at least $55 million of consolidated EBITDA for the trailing four-quarter period ending September 30, 2025 and for each trailing four-quarter period after that. This sets a clear performance threshold the company needs to meet to stay in compliance with its credit facility.